Pharmacological Mechanism of Kratom
Kratom works primarily as an atypical opioid agonist, with its main alkaloids—mitragynine and 7-hydroxymitragynine—acting as partial agonists at mu-opioid receptors (μ-OR) and competitive antagonists at kappa- and delta-opioid receptors 1, 2.
Primary Mechanism: Opioid Receptor Activity
The core mechanism involves G protein-biased agonism at mu-opioid receptors, which distinguishes kratom from classical opioids and may explain its reduced respiratory depression risk 2. The two principal alkaloids demonstrate:
- Mitragynine and 7-hydroxymitragynine: Partial agonists at mu-opioid receptors (MOR)
- Antagonist activity: At kappa-opioid receptors (KOR) and delta-opioid receptors
- G protein-biased signaling: This selective pathway activation produces analgesic effects while potentially minimizing beta-arrestin-mediated respiratory depression 2
Secondary Receptor Interactions
Beyond opioid receptors, kratom alkaloids interact with multiple neurotransmitter systems 3, 1:
- Adrenergic receptors: Contributing to stimulant effects at lower doses
- Serotonergic receptors: Mediating mood-elevating properties
- Dopaminergic pathways: Involved in reward and energy effects
Dose-Dependent Parabolic Effects
Kratom exhibits a unique dose-dependent pattern 3:
- Low doses: Stimulant effects predominate (via adrenergic/dopaminergic activity)
- Higher doses: Opioid-like analgesic and sedative effects emerge (via mu-opioid agonism)
Additional Mechanisms
The pharmacology extends to 4:
- Modulation of neuronal Ca²⁺ channels
- Effects on cAMP and CREB protein expression
- Activation of descending monoaminergic systems
Critical Safety Considerations
Despite the theoretical reduced respiratory depression compared to traditional opioids, kratom carries significant risks 1, 5:
- Physical and psychological dependence: Classic opioid withdrawal symptoms occur upon cessation
- Liver toxicity: Predominantly cholestatic injury patterns, with some cases progressing to transplantation 5
- Drug interactions: Modulation of CYP450, P-glycoprotein, and UGT enzymes potentiates toxicity of co-administered medications 1
- Polysubstance complications: Most adverse events involve concurrent substance use
The lack of standardization in kratom products creates unpredictable alkaloid concentrations, making dosing unreliable and increasing toxicity risk 6. The FDA-labeled kratom products in the evidence appear to be topical formulations 7, which do not reflect the oral consumption patterns associated with systemic opioid-like effects.